Navigation Links
Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
Date:4/9/2008

atient-years) for comparator-treated patients. There were too few cases to determine whether the emergence of these events is related to Exubera. All patients who were diagnosed with lung cancer had a prior history of cigarette smoking."

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development platforms. Nektar PEGylation and pulmonary technology, expertise, manufacturing capabilities have enabled ten approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

This press release contains forward-looking statements regarding management's plans and expectations for Nektar's business including the potential of its product pipeline. These forward-looking statements involve risks and uncertainties, including but not limited to: (i) the Nektar's proprietary product candidates and those of certain of its partners are in the early phases of clinical development and pre-clinical development and the risk of failure is high and can unexpectedly occur at any stage, (ii) the timing or success of the commencement or conclusion of planned clinical trials is subject to a number of uncertainties including but not limited to clinical design, patient enrollment, regulatory requirements and clinical outcomes, (iii) Nektar's or its partner's success in meeting minimum clinical end points and obtaining regulatory approvals for product candidates, (iv) Nektar may not successfully complete new collaborative partnerships with respect to its product candidates, or if any partnerships Nektar does negotiate do not include sufficiently favorable commercial terms, Nektar may not receive
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
2. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
3. OPKO Health and Pathogenics Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection
4. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
5. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
6. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
7. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
8. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
9. Potential Early Warning System for Lung Cancer Identified
10. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
11. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 According ... Market by Extraction type (SFE, Cold Pressed, Organic ... Care, Pharmaceutical, Food Supplements, Fragrance, & Others) - Global ... defines and segments the Amaranth Seed Oil Market ... size in terms of value. The Amaranth Seed ...
(Date:8/29/2014)... 2014 According to the ... Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User ... Gene Synthesis, NGS, DNA, RNAi) - Global Forecast ... Synthesis Market is expected to reach $1,712.1 Million ... at a CAGR of 9.8% from 2014 to ...
(Date:8/29/2014)... -- In part four of a blog series ... a strategic asset, Mary Baxter, MBA, RPh ., ... Innovation Delivery Solutions business, discusses how expanding patient access ... patients. "Every hospital pharmacist knows that filling ... in a value-based healthcare world," Baxter says. "For the ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a biopharmaceutical company ... Tom Wegman , will present at the upcoming Jefferies & Company 2010 ... 2:30pm EDT . , ... A live webcast of the presentation can be accessed under "Calendar ...
... Questcor Pharmaceuticals, Inc . (Nasdaq: QCOR ) announced today ... Thursday, June 10, 2010 at The Grand Hyatt Hotel in ... Executive Officer, will discuss the Company,s business strategy and historical financial performance at ... , , ...
Cached Medicine Technology:BioSpecifics Technologies Corp. to Present at Jefferies & Company 2010 Global Life Sciences Conference 2BioSpecifics Technologies Corp. to Present at Jefferies & Company 2010 Global Life Sciences Conference 3Questcor to Present at the Jefferies 2010 Global Life Sciences Conference 2
(Date:9/1/2014)... 01, 2014 Ontraport , one ... that was developed to automate the small intricacies of ... of Shane Michaels, prompting an investigative review. , ... duty of managing all of the small details involved ... overwhelming,” reports Michaels. “That’s why Ontraport has become so ...
(Date:9/1/2014)... 2014 AttorneyOne.com, a recognized authority on ... information from the FDA on DePuy Synthes Craniomaxillofacial ... on August 28, that specific lots of DePuy Synthes ... as the device may reverse directions after surgery. ... Distraction System is an implant used to lengthen and/or ...
(Date:9/1/2014)... Nevada (PRWEB) September 01, 2014 Beginning ... to over 3,000 medical professionals and 10,000 consumers for ... is a 5-day gathering of the nation’s top medical ... associated diseases or conditions. The week-long event contains more ... evidence-based scientific instruction available in the pain management field. ...
(Date:8/31/2014)... 31, 2014 An analysis of 32 ... has revealed a link between lower levels of Vitamin ... in the August 2014 issue of American ... main form of Vitamin D found in blood. ... 25-Hydroxyvitamin D lower than 9 nanograms/milliliter (ng/mL) were twice ...
(Date:8/31/2014)... (PRWEB) August 31, 2014 The FDA ... Nutrition Facts label. If adopted, the proposed changes would ... addition of “added sugars” on the label, and a ... to keep “added sugars” off the label. NutriGold fully ... consumers make healthier food choices. “After 20 years, it's ...
Breaking Medicine News(10 mins):Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:Medical Marijuana Doctor Company Set to Present at Las Vegas Pain Week 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 3Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 4Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 2Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 3Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 4
... of a new use for magnetic levitation, or "maglev," ... trains to float above the tracks. In ACS, bi-weekly ... describe putting maglev to use in an inexpensive sensor ... Whitesides and colleagues note that measurements of a substance,s ...
... in Spanish . Ensuring the optimum ... in prostate cancer treatment manages to control the illness in ... research undertaken at the University Hospital of Navarre and published ... the American Society of Brachytherapy. As is known, brachytherapy ...
... (June 23, 2010) Children who experience maltreatment ... likely to experience frequent headaches, including chronic migraine, as ... Headache Society,s 52nd Annual Scientific Meeting in Los Angeles ... Experiences (ACE) Study of 17,337 adult members of the ...
... Some 19 percent of soldiers returning from Iraq have ... While prevalence of migraine among the U.S. military ... quality in soldiers with chronic headaches including post-traumatic headache ... Army Medical Center in Tacoma, WA presenting at American ...
... having the most expensive health care system, the United ... countriesAustralia, Canada, Germany, the Netherlands, New Zealand, and the ... areas: quality, efficiency, access to care, equity and the ... a new Commonwealth Fund report. While there is room ...
... research professor in the department of physics at NJIT, ... Research Council (NRC) of the National Academies ( www.nationalacademies.org ... vehicles in the aftermath of Toyota,s large recalls. The ... and July 1, 2010 in Washington, DC, includes notable ...
Cached Medicine News:Health News:Optimizing brachytherapy dose on the same day as the implant can control prostate cancer 2Health News:US ranks last among 7 countries on health system performance 2Health News:US ranks last among 7 countries on health system performance 3Health News:NJIT professor heads panel studying sudden car acceleration 2
The modular, high-end stereomicroscope; meets even the most critical demands in research and quality control provides high-contrast images with excellent depth of field and color fidelity...
6.3X Zoom Ratio - Boasting magnifications from 0.8X to 5X, the twin zooming objective optical system developed exclusively by Nikon provides a zoom ratio of 6.3:1. Clickstops at 1X intervals allow ob...
Fixed Versatility - With a diverse selection of body tubes, stands, lighting techniques and Nikon's world-renowned optics, this modular microscope can be configured to fit nearly any application....
... designed to have the following properties and ... sections, cell cultures, specimens with aqueous embedding ... cover glass thickness (0.14...0.18 mm) and temperatures ... correction collar can also be used for ...
Medicine Products: